# A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct07003074/  
OnCo record `nct07003074` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing TQB2102 in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, now recruiting.

## Summary

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT07003074, led by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Open, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) Positive Recurrent or Metastatic Breast Cancer. Planned enrolment is 642 participants (estimated). The study started in 2025-06-23 and primary completion is expected in 2029-07. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07003074
- Phase: 3
- Setting: A Randomized, Open, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) Positive Recurrent or Metastatic Breast Cancer
- Sponsor: Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical
- Enrolled: 642

## Sources

- ClinicalTrials.gov NCT07003074: https://clinicaltrials.gov/study/NCT07003074

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [TQB2102](https://onco.cc/drugs/tqb2102/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct07003074.json